Login to Your Account



J&J Is First Taker for Affimed Therapeutics' Tandab Technology

By Cormac Sheridan
Staff Writer

Tuesday, July 16, 2013
Affimed Therapeutics AG secured a first deal for its bispecific tandem diabody (Tandab) technology, with Johnson & Johnson. The agreement is being executed indirectly, through the financing of a single-asset subsidiary of Affimed, called Amphivena Therapeutics Inc., which has in-licensed an Affimed program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription